Introduction

The Indian pharmaceutical market continues to evolve with the rise of several key players, including Laurus Labs and the often-confused Larus Pharma. While Laurus Labs is a listed entity actively traded on the National Stock Exchange (NSE), Larus Pharma is more known in international circles, particularly in Italy. This article will clarify the differences and focus mainly on Laurus Labs’ share performance, its listing on NSE, and the stock's historical behavior. Additionally, we will explore the confusion surrounding Larus Pharma, which has contributed to investor curiosity.

Larus Pharma Share Price

Larus Pharma Share Price: Many investors, particularly those new to pharmaceutical stocks, often search for "Larus Pharma share price" expecting to find a stock listed in India. However, it is important to clarify that Larus Pharma is not listed on the Indian stock exchanges, including the NSE or BSE. Larus Pharma is a European pharmaceutical company based in Italy, primarily focused on research, development, and marketing of dermatological and skincare products.

Since Larus Pharma is not publicly listed, it does not have a share price available on any public financial platforms such as NSE India or Bloomberg. Instead, investors might be referring to Laurus Labs, an Indian pharmaceutical giant that is publicly listed and actively traded. Retail investors and internet users are frequently confused due to the similarity between the two names.

Therefore, it is essential to distinguish between the two: Larus Pharma is not publicly traded, while Laurus Labs is, making the latter the subject of share price analysis and historical market data in the following sections.

Laurus Labs Share Price In NSE

Laurus Labs Share Price In NSE: Laurus Labs Limited is a prominent name in the Indian pharmaceutical and life sciences sector. Their business revolves around developing APIs, manufacturing drug formulations, and offering synthesis support. The company was listed on the National Stock Exchange (NSE) in December 2016 under the symbol LAURUSLABS.

As of June 2025, Laurus Labs’ share price trades in the range of ₹370 to ₹420, reflecting the general market conditions, investor sentiment, quarterly performance, and broader pharmaceutical trends. Over the past few years, the stock has seen significant volatility:

• In 2020, during the COVID-19 pandemic, the stock surged over 200% due to strong API demand.
• In 2021 and 2022, it experienced some correction due to pressure on margins and changing API demand cycles.
• In 2024 and 2025, Laurus Labs showed signs of recovery backed by new product pipelines and international contracts.

Laurus Labs is considered a mid-cap pharma stock and is included in various indices such as the Nifty Healthcare Index. Its performance is often compared with peers like Divi’s Labs, Aurobindo Pharma, and Granules India.

For investors, Laurus Labs offers a mix of growth potential and operational consistency, making it a stock to watch in the Indian pharmaceutical segment.

Larus Share Price History

Larus Share Price History: Since Larus Pharma is not a listed entity, there is no share price history available for it. However, Laurus Labs' share price history on the NSE gives us valuable insight into the stock’s performance and investor confidence over the years.

Here is a quick overview of Laurus Labs’ price history since its IPO:

• The IPO of Laurus Labs in 2016 priced the stock around ₹428, but the share price remained quiet during the initial period.
• From 2017 to 2019, Laurus Labs traded in a tight range of ₹300–₹400, showing consistent yet moderate growth.
• 2020: A breakout year for Laurus Labs. The stock price soared past ₹600 due to the COVID-19 tailwinds in the API segment.
• 2021: The rally continued for a while, with the price peaking at around ₹710 in early 2021.
• 2022-2023: A correction phase brought the price back to ₹400 levels, primarily due to reduced pandemic-related demand and pricing pressures.
• Through strategic portfolio expansion in 2024–2025, Laurus Labs managed to regain support from the investing community.

 Investors witnessed a phase of healthy price stability, with the stock hovering around the ₹350–₹450 mark.

• The share price trajectory reflects Laurus Labs’ resilience, product innovation, and leadership in the pharmaceutical supply chain. Long-term investors who entered during its IPO have seen considerable returns despite market fluctuations.

Conclusion

Conclusion: The confusion between Larus Pharma and Laurus Labs is common but needs clarification. Larus Pharma is a private Italian pharmaceutical company with no listed shares on any Indian or international stock exchange, and hence, has no available share price or trading history. In contrast, Laurus Labs is a reputable Indian pharmaceutical company listed on the NSE, with a well-documented share price performance since its IPO in 2016.

Investors should focus on verified ticker symbols and company disclosures before making any decisions. Laurus Labs, with its consistent performance and sector leadership, offers a credible option for those interested in the pharma sector. For accurate stock tracking, always refer to NSE India’s official site or financial tools like Moneycontrol, Investing.com, or Bloomberg.

In summary, understanding the difference between Larus and Laurus helps eliminate confusion and encourages smarter investment strategies in the pharmaceutical equity space.